Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex.
Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex. Oncotarget. 2020 May 12;11(19):1758-1776 Authors: Miranti CK, Moore S, Kim Y, Chappeta VR, Wu K, De B, Gokhale V, Hurley LH, Reyes-Reyes EM Abstract The androgen receptor (AR) is a major driver of prostate cancer development and progression. Men who develop advanced prostate cancer often have long-term cancer control when treated with androgen-deprivation therapies (ADT). Still, their disease inevitably becomes resistant to ADT and progresses to castration-resistant prostate cancer (CRPC). ADT involves potent competitive AR antagonists and androgen synthesis inhibitors. Resistance to these types of treatments emerges, primarily through the maintenance of AR signaling by ligand-independent activation mechanisms. There is a need to find better ways to block AR to overcome CRPC. In the findings reported here, we demonstrate that the nuclear scaffold protein, nucleolin (NCL), suppresses the expression of AR. NCL binds to a G-rich region in the AR promoter that forms a G-quadruplex (G4) structure. Binding of NCL to this G4-element is required for NCL to suppress AR expression, specifically in AR-expressing tumor cells. Compounds that stabilize G4 structures require NCL to associate with the G4-element of the AR promoter in order to decrease AR expression. A newly discovered G4 compound that suppresses AR expression demonstrates selective killing of AR-expressing tumor cells...
Publication date: Available online 12 July 2020Source: Seminars in Cancer BiologyAuthor(s): Bo Ma, Alan Wells, Liang Wei, Junnian Zheng
Publication date: Available online 12 July 2020Source: Acta Pharmaceutica Sinica BAuthor(s): Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang
CONCLUSION: According to the results of the specificity tests, the designed aptasensor did not show any significant interactions with other analytes in real samples. Clinical functionality of the aptasensor was appraised in serum samples of healthy individuals and patients examining the PSA level through the fabricated aptasensor and the reference methods. Both methods are comparable in sensitivity. The present fabricated PSA aptasensor with substantial characteristics of ultra- sensitivity and cost-effectiveness can be conventionally built and used for the routine check-up of the men for prostate problems. PMID: 3264...
This study aimed to reconstruct the dose distribution of single fraction of stereotactic body radiotherapy for patients with prostate cancer using cone-beam computed tomography (CBCT) and a log file during volumetric-modulated arc therapy (VMAT) delivery with flattening-filter-free (FFF) mode. Twenty patients with clinically localized prostate cancer were treated with FFF-VMAT, and projection images for in-treatment CBCT (iCBCT) imaging were concomitantly acquired with a log file. A D95 dose of 36.25 Gy in five fractions was prescribed to each planning target volume (PTV) on each treatment planning CT (pCT). Deformed...
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Roderick C.N. van den Bergh, Olivier Rouvière, Theodorus van der Kwast, Erik Briers, Thomas Van den Broeck, Philip Cornford, Marcus G. Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Nikolaos Grivas, Jeremy Grummet, Thomas B. Lam, Michael Lardas, Matthew Liew, Lisa Moris, Malcolm D. Mason, Nicolas Mottet, Daniela E. Oprea-Lager
CONCLUSION: The perioperative management of prostatectomy in France is relatively homogeneous, between urologists. The length of hospital stay remains important and could be reduced by proposing an ERAS protocol as has been obtained for cystectomy. LEVEL OF EVIDENCE: III. PMID: 32646841 [PubMed - as supplied by publisher]
Publication date: Available online 9 July 2020Source: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)Author(s): J.R. García, A. Compte, M. Buxeda, S. Mourelo, M. Soler, A. Blanch, E. Valls, E. Riera
Publication date: Available online 9 July 2020Source: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)Author(s): J.R. Garcia, M. Cozar, M. Soler, P. Bassa, E. Riera, M. Buxeda, E. Valls, J. Ferrer
Multiple forms of definitive radiotherapy are acceptable alternatives to more prolonged radiotherapy regimens for men with intermediate-risk prostate cancer (PCa) and can be considered for men with low-risk disease who decline active surveillance. Stereotactic body radiotherapy (SBRT) is an external beam radiotherapy modality in which large radiation doses are delivered over five or fewer fractions. Two forms of brachytherapy -- permanent seed implant low dose rate brachytherapy (LDR-BT) and temporary interstitial implant high dose rate brachytherapy (HDR-BT) -- are also options.